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CHAPTER 1
INTRODUCTION

1.1. Parkinson's disease:
Parkinson's disease (PD) is a complex progressive neurodegenerative disorder
characterized by uncontrollable tremors, rigidity, slowness of movement, bradykinesia and
postural imbalances. PD also has symptoms of depression as well as dementia. It is first
described by Dr. James Parkinson in 1817 as ‘shaking palsy’.1 It is estimated that PD affects 12% of the people older than 65 years of age. The severity and symptoms of PD varies according
to the stage of the disease.2 The pathological hallmark of PD is loss of dopaminergic neurons in
the substantia nigra pars compacta (SNPc) region of the brain.3 Other major pathological
features of the PD include presence of α-synuclein rich cytoplasmic filamentous protein
aggregates called Lewy bodies in dead or dying neurons of the SNPc, mitochondrial dysfunction
due to oxidative stress, increased amounts of iron, etc. Most of the pathological features of PD
appear when about 75% of the nigral dopaminergic neurons are degenerated.4 Progressive
degeneration of dopaminergic neurons leads to profound striatal dopamine deficiency (Figure 1).
Thus, dopamine deficiency in the SN region leads to motor symptoms and worsen as dopamine
depletes further.
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Figure 1. Schematic diagram showing nigrostriatal dopaminergic pathway 5

1.2. PD prevalence in US and World-wide:
PD is the second most-prevalent neurodegenerative disorder in the western world after
Alzheimer's disease.

According to a statistical analysis published by the PD foundation,

approximately 60,000 Americans are diagnosed with PD each year, and an estimated seven to
ten million people worldwide are living with PD. It was also estimated that PD affects 1% of the
population at age 65 to 5% at age 85.6 Incidence of PD increases with age, but about 15% of
people with the condition develop "young-onset" PD before reaching at the age 50. Men are
more prone to have Parkinson's disease than women. Most cases of PD occur in people with no
apparent history of the disorder in their family. However, approximately 15 percent of people
with PD have a family history of this disorder. The research from the past two decades in PD
area has provided the basic pathogenetic factors of PD such as roles of oxidative stress,
aggregation of α-synuclein protein and the presence of iron. The cost of PD treatment is
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estimated to be nearly $25 billion per year in the United States alone. Medication costs for an
individual patient averages about $2,500 a year.

1.3. Pathogenetic Factors of PD:
As the fundamental reasons for the development of PD remain still unclear, this aspect is
an object for intensive research. However, many factors have been shown to be involved in the
development of PD such as oxidative stress, protein aggregation and mitochondrial dysfunction.
Each of these phenomena may lead to the development of the neurodegenerative process.

1.3.1. Oxidative Stress:
Oxidative stress has been linked to both the initiation and the progression of PD.7
Oxidative stress and subsequent cell death could develop in the SN in circumstances where a)
increased dopamine turnover leads to increased peroxide formation; b) a deficiency in
antioxidants (Glutathione and Superoxide Dismutase) thereby diminishing the capacity to clear
H2O2; or c) an increase in iron content, which can lead to hydroxyl radical formation.8
Postmortem studies of PD brains also suggested elevated levels of iron which gets involved in
Fenton reaction to produce reactive oxygen species (ROS).9

This oxidative damage

subsequently causes damage to important cellular components such as lipid, protein and DNA.
Cellular oxidation produces superoxide anion (O2.-), hydrogen peroxide (H2O2) and
hydroxyl radical (OH.) which are collectively known as reactive oxygen species (ROS). Under
normal conditions, the body’s antioxidant mechanisms such as glutathione peroxidase, catalase
and superoxide dismutase counterbalance the free radicals. Oxidative stress is a redox imbalance
with an excess formation of ROS or dysfunction/deficiency in antioxidant mechanism of the
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body.10 Apart from PD, oxidative stress also has been implicated in the pathogenesis of many
other neurodegenerative diseases.11 The brain is more susceptible to damage by ROS due to the
presence of high amount of polyunsaturated fatty acids, low level of antioxidants and elevated
amount of iron in the specific regions of the brain.

1.3.2. Sources of oxidative stress
1.3.2.1. Dopamine metabolism
Monoamine oxidase B (MAO-B) catalyzes the oxidative deamination of dopamine in the
substantia nigra and striatum and forms hydrogen peroxide (Figure 2). The level of MAO-B
enzyme increases with age.12 Moreover, H2O2 produced in the glial cells can cross into the
nearby dopaminergic cells, where it can potentially react with free iron and produces toxic
hydroxyl radical which can damage cellular components.

Figure 2. Dopamine metabolism by enzyme monoamine oxidase B (MAO-B).
Dopamine is highly susceptible for auto-oxidation to form dopamine quinones which acts
as a major source for the generation of free radicals (Figure 3). Catecholamines are also known
to react with oxygen non-enzymatically to form quinones or semiquinones by auto-oxidation.
Hydrogen peroxides and oxyradicals are also generated in this process. Quinones and
semiquinones bind to the cellular DNA, lipids and proteins rendering it toxic to the cell. Auto
oxidation of dopamine and processing of free radicals are important factors in determining the
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health of dopaminergic nigrostriatal neurons. Auto oxidation has been proposed to be a
mechanism of neuronal cell loss in PD.

Figure 3. Structures of different auto-oxidation products of dopamine.
Nitric oxide (NO) also leads to the degeneration of dopaminergic neurons in the SN.
Although the exact mechanism of neuronal degeneration by nitric oxide is not yet well
understood, it has been suggested that increased expression of iNOS or nNOS and peroxynitrite
may lead to neuronal death in PD patients. NO is known to inhibit complexes I and IV of the
mitochondrial electron transport chain. Therefore, NO and reactive nitrogen species can cause
increased oxidative stress and degeneration of dopaminergic neurons.
Cellular oxidation produces H2O2 and free radicals, which are counterbalanced by the
body’s antioxidant mechanisms as mentioned previously. Glutathione, catalase, super oxide
dismutase, cysteine, ascorbate, tocopherol are the major antioxidant systems present in the cells.
H2O2, generated by MAO (a mitochondrial enzyme) is scavenged by glutathione (GSH)
peroxidase, leading to the formation of glutathione disulfide (GSSG) (Figure 4). Normally,
GSSG is efficiently reduced by glutathione reductase to form GSH. Due to this, levels of GSSG
in various tissues including brain, constitute only 1% or less of the total glutathione i.e, GSH +
GSSG. However, in cases of increased exposure of tissues to peroxides or peroxide-generating
cell toxins, the levels of GSSG can rise. The ratio of oxidized to reduced glutathione reflects the
redox state of the tissue.13
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Glutathione is a key antioxidant and depletion of GSH would diminish the capacity to
clear H2O2.14 The peroxisomes contain catalase enzyme which decomposes hydrogen peroxide.
This H2O2 neutralizing capacity can be compromised during pathological conditions leading to
the release of H2O2 into the cytosol which can contribute to oxidative stress. GSH loss and
alteration of the cellular redox state can lead to decrease of the GSH/GSSG ratio.

Figure 4. Decreased detoxification related Oxidative stress.

1.3.2.2. Role of iron in oxidative stress
In the PD brain, iron plays a major role in production of oxidative stress. It has been
reported that iron concentration in the PD brain is 10 to 20 times more than its concentration
under normal physiological state.15 Iron along with H2O2 can undergo non-enzymatic Fenton
reaction to produce hydroxyl radical. There is a substantial role of iron in oxidative stress in the
PD brain. The substantia nigra is rich in iron content in the PD brain as compared to normal
person.16 Neuromelanine, which is believed to be formed by the auto-oxidation of dopamine,
allows Fe3+ from of Iron to bind.17 In this way, melanine enhances -OH. Radical formation by
reducing bound Fe3+ to Fe2+ (Figure 5).

Figure 5. Fenton reaction by which H2O2 forms hydroxyl radical in iron rich environment.
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Overall, increased concentration of iron and H2O2 from dopamine metabolism lead to
enhancement of the vulnerability of SN neurons towards oxidative stress. The level of non-heme
iron concentration increases with age in SN region of the brain.18 It has been shown in the
literature that amount of iron content is directly correlated to motor dysfunction.19,20 Further,
exposure to toxins such as MPTP and 6-hydroxy dopamine raises iron level in the substantia
nigra region of brain.21

Figure 6. Iron and oxidative stress hypothesis of Parkinson’s disease.18a

1.3.2.3. Role of mitochondrial dysfunction in oxidative stress
The mitochondrion is considered to be the energy (ATP) generating machine of a cellular
body. Molecular oxygen utilization is coupled to this large scale energy production. ATP
production is coupled to the electron transfer through complexes I, III, and IV via a proton
gradient generated at these three sites (Fig. 7).22 Molecular oxygen is then reduced to form water
at complex IV. However, the integrity of passage of electrons down the chain is not at 100%.22 It
was demonstrated that complex I was deficient in the skeletal muscle, substantia nigra, and
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platelets of PD patients.23 About 1-2% of the total amount of O2 reduced can form superoxide
radical at the level of complex I.24 Mitochondrial dysfunction, due to increased superoxide
radical formation, is a potential cause of neuronal death.

Figure 7. The mitochondrial electron transport chain and potential sites for superoxide radical
formation.25

1.3.3. Protein aggregation
The presence of proteinaceous cytoplasmic inclusions called “Lewy Bodies” is a
pathological hallmark of PD. Protein α- synuclein is a major component of LB. Due to its
unfolded nature, α-synuclein is prone to self aggregation under various conditions and causes
aggregation of other proteins, a property that may underlie its involvement in LB formation and
its contribution to the pathogenesis of PD.26 In addition to α-synuclein, many other proteins are
post-translationally modified and accumulate in the SN and other brain regions. The
mitochondria-derived ROS inhibits mitochondrial respiration and promotes the aggregation of
alpha synuclein protein (αSN), which ultimately forms lewy bodies (LBs) and some glial cell
cytoplasmic inclusions.27 The common observations for the involvement of ASN aggregation in
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PD are: ASN is a component of Lewy bodies which is the cardinal hallmark of PD pathology.27b
Secondly, familial early onset of PD is caused by over-expression of ASN due to mutation of
SNCA gene.27a, 28 Third, ASN forms toxic oligomers or fibrils. Currently it is not known how the
aggregation of ASN triggers cell death, but it has been postulated that soluble oligomeric form of
ASN, known as protofibrils, are the major culprit.

1.3.4. Genetic factors
In the last two decades, numerous findings have implicated various genes that may
increase the susceptibility to PD. Cases of young-onset PD have shown to be significantly
related to genetic inheritance. About 10% of PD patients report a positive family history.29
Initially, linkage analysis which analyzed multiple family members affected by Mendelian PD,
revealed rare genetic variant which has high penetrance effect. On the other hand, genome wide
association analysis compared control and case subjects and identified statistically significant
genetic variants with incomplete penetrance responsible for sporadic PD. Both approaches
yielded some genes which overlap. Thus, PD is now considered to be a complex disease
resulting from interaction of environment/gene and/or gene/gene.
More than 13 loci and 9 genes are associated with autosomal dominant or autosomal
recessive form of PD (Table 1.1).30 Identified genes can be divided into: causal genes and
associated genes. Causal gene alone without any interference of other environmental factors or
genes causes PD in person who inherits it. Whereas, associated gene does not cause PD but
increase the possibility of developing it. Associated gene’s interaction with other environmental
factors or genes can trigger PD in the person who inherits it. PARK2, PARK7 and SNCA are
causal genes, whereas, LRRK2 is an associated gene.
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PARK Loci

Gene

Forms of PD

Mutations

PD-associated loci and genes with conclusive evidence
PARK1/PARK4

SNCA

EOPD, AD and

A30P, E46K, A53T

sporadic

Genomic
duplications/triplications

PARK 8

LRRK2

LOPD, AD and

40 missense variants, >7 of

sporadic

them pathogenic, including the
common G2019S

PARK2

Parkin

Juvenile and EOPD,

>100 mutations (point

AR and sporadic

mutations, exonic
rearrangements)

PARK6

PINK1

ARPD

>40 point mutations, rare large
deletions

PARK7

DJ-1

EOPD AR

>10 point mutations and large
deletions

PARK9

ATP13A2

Juvenile AR

>5 point mutations

Kuforakeb
syndrome and
EOPD
Table 1.1. Loci genes and susceptibility factors involved in PD. EO, Early onset; LO, Late
onset; AD, Autosomal dominant; AR, Autosomal recessive; PD, Parkinson’s disease;
SNCA, α-synuclein; LRRK2, Leucine-Rich Repeat Kinase-2; PINK1, PTEN-Induced
Kinase 1.30
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SNCA (α-synuclein) has been clearly shown to be involved in pathophysiology of
sporadic and familial PD. It is the major component of Lewy bodies and Lewy neuritis found in
PD patients. A30P, E46K and A53T are the 3 major mutations found in SNCA gene.28,31,32 All
three mis-sense mutations in SNCA are extremely rare. However, all patients with mis-sense
mutations have early onset of disease and dementia with Lewy bodies. Duplication and
triplication of the locus containing SNCA support the hypothesis that an increase in α-synuclein
concentration is toxic.33,27a Early stage patients with SNCA duplication resemble patients with
idiopathic PD. Interestingly, patients with SNCA triplication have earlier onset, faster disease
progression, marked dementia and frequent dysautonomia.34

1.4. Therapy in PD:
1.4.1. Levodopa Therapy:
Levodopa (L-DOPA), one of the main stream therapies became available in 1960s for the
treatment of PD and is still being considered.35 The symptoms of PD show dramatic
improvement with L-Dopa administration. However, long-time L-dopa administration is
associated with major side effects such as abnormal involuntary movements, dyskinesia,
freezing, dementia, etc.36 L-Dopa can provide prominent symptomatic relief but cannot stop the
progression of underlying disease,37 rather it might accelerate dopaminergic neuronal
degeneration.4 Over the years, numerous strategies have been developed to overcome this
problem. As an adjunct to L-dopa therapy, Dopamine agonists have been used to reduce
oxidative stress as well as L-dopa related motor complications. Dopamine agonists interact with
DA autoreceptors, down-regulating the synthesis and release of dopamine; reducing oxidative
stress. Many clinical studies have shown promising results with DA agonist monotherapy
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alone.38 However, dopamine agonist monotherapy reduces the motor symptoms in the early
stages of PD patients but eventually patient requires L-dopa therapy. Treatment with dopamine
receptor agonists in early PD is beneficial as it delays the initiation of L-dopa therapy. The
advantage of using combination therapy of dopamine agonists and L-dopa is that it slows down
the increase of required L-dopa dose. Therefore, the motor complications associated with the use
of L-dopa are much less in combination therapy. So, the current strategy of PD therapy is to
delay the initiation of L-dopa therapy, slow down the increase of L-dopa requirement or extend
the period of L-dopa treatment.
Clinical studies also showed that initial therapy with MAO-B inhibitors delayed initiation
of L-dopa therapy. Catechol-O-methyl transferase (COMT) inhibitors inhibit the peripheral
metabolism of L-Dopa; increasing the half life of L-Dopa in the brain. However, none of these
strategies address the limitations of L-dopa. Therefore, the need of therapeutic agents, which will
have disease modifying effect is of high importance.36

1.4.2. Neuroprotective therapy:
The development of a neuroprotective therapy that delays, prevents, or reverses
neurodegeneration in PD is the chief choice of treatment. Current therapies of PD target at
providing symptomatic treatment only without addressing the basic pathogenetic factors of the
disease process. As discussed earlier, there is a need to develop neuroprotective therapies
addressing the the major pathogenetic factors such as - oxidative stress, ASN aggregation,
mitochondrial dysfunction, and excessive amount of iron. Therefore, an ideal drug candidate
would also act as ASN aggregation modulator, antioxidant, iron chelator and neuroprotective
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while providing symptomatic relief.

Research improvements towards multifunctional drug

candidates for the treatment of PD addressing the possible issues are greatly appreciated.

1.5. An Overview of dopamine receptor system:
DA neurons and their associated receptors have been known to be implicated in the
pathogenesis of PD. The DA receptors belong to the super-family of membrane-bound proteins,
termed as G-protein coupled receptors (GPCR). Until late 20th century, the DA receptor
population of the brain was believed to consist of only two subtypes, D1 and D2.39 Cloning of
these two receptors led to the discovery of numerous additional low-abundance DA receptors,
including the D3, D4 and D5 subtypes. Extensive studies on these two receptor systems by
various in vitro and in vivo techniques including behavioral, physiological, neurochemical,
pharmacological and molecular approaches revealed some of the basic properties of these two
receptor systems.
The D1-like receptors, including D1 and D5, are stimulatory in nature, thereby activating
the second messenger, adenylyl cyclase to produce cAMP (Cyclic adenosine monophosphate).
In contrast, D2-like receptors, including D2, D3 and D4, are negatively coupled to adenylyl
cyclase and the production of cAMP.40 Both D1 and D2 receptors exist in high affinity states for
dopamine agonists. Initially, Sokoloff et al. cloned the D3 receptor from rat cDNA library in
1990.39 This was followed by the cloning of the human D3, D4 and D5 receptor subtypes.41,42
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Figure 8. Classification of Dopamine Receptors in CNS.
(Source: Goodman & Gilman's, the Pharmacological Basis of Therapeutics, 12ed, 13.7)

1.5.1. Human D2 and D3 receptor - A Comparison:
Human D2 and D3 receptors display a very high degree of amino acid sequence
similarity. To date, three different splice variants for the D2 receptor have been identified. These
include the D2 short form of 414 amino acids, the D2 long form containing 443 amino acids, and
the D2 longer form, which contains 445 amino acids.43 The differences in length of the splice
variants give rise to differences in the size of the large intracellular loop (IL 3). However, only a
single functional splice variant of human D3 receptor has been identified.44 The overall amino
acid similarity between human D2 and D3 receptors is 55%, and this increases to around 90% in
the ligand recognition sites.45 This high degree similarity of structural homology makes
designing selective D3 ligands very challenging. In general, dopamine and several dopaminergic
agonists show a higher binding affinity for D3 compared to D2. Antagonist binding affinity is
slightly higher for D2.46 Human D3 receptors are confined mainly to the mesolimbic areas of the
brain, whereas D2 receptors are found in all dopaminergic regions of the brain. Activation of D2
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and D4 receptors results in a strong inhibition of cAMP accumulation, whereas in the activation
of D3 receptors, cAMP accumulation is modest or even absent, which indicates a weak coupling
of D3 to inhibitory G-proteins.47

1.6. The use of dopamine agonists in neuroprotective therapy of PD
Dopamine agonists as an initiating therapy can delay the introduction of L-dopa for
months to years. Lesser amounts of L-dopa administration gives rise to a lower level of ROS
formation, resulting in less oxidative stress that ultimately causes neuronal degeneration. Studies
in PD animal models have demonstrated that the levels of striatal dopamine and their metabolites
are considerably higher in animals treated with L-dopa compared to the level of dopamine
agonists, despite comparable behavioral effects.48
Dopamine D2/D3 receptors are located pre and post synaptically. Dopamine D2/D3
receptor agonists have the potential to stimulate the presynaptic auto receptors on dopaminergic
neurons and thereby inhibit dopamine synthesis, release and metabolism to form ROS.49 In vitro
studies demonstrated that the addition of the DA receptor agonist pramipexole to cultured
dopaminergic neurons induces a dose dependant decrease in dopamine concentration in the
medium.50 In vivo studies have similarly shown that a variety of dopamine agonists, including
quinpirole, apomorphine and pramipexole, can decrease in vivo dopamine turnover, as
determined by (DOPAC+ HVA)/Dopamine ratio as well as dopaminergic neuronal firing.50

16

Figure 9. Structures of D2/D3 selective agonists with preferred D3 selectivity.

1.7. Rationale for targeting D3 receptors in PD
Although it has been assumed that stimulation of D2 receptor is necessary for antiparkinsonian activity, DA agonists used in the treatment of PD have higher affinity for the D3
receptor. It is thought that meso-limbic dopamine system (where D3 receptors are most dense)
could play a role in anti-parkinsonian relief, as the limbic striatum is known to be involved in
aspects of movement, such as locomotor activity and goal-directed behaviors. Locomotor
stimulatory activity is observed in 6-OHDA-lesioned rats at the same doses of D3-preferring
agonists that are inhibitory in normosensitive rats, suggesting that D3-preferring agonists may be
a viable option for anti-parkinsonian treatment of DA depleted animals.51
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1.8. Neuroprotective effect of D3 preferring agonists:
Most neuroprotection studies are conducted using the well known D3 receptor selective
agonist pramipexole, which indicates a possible connection of neuroprotection by D3-preferring
agonism.52 In two in-vivo experiments involving D3-preferring agonists, pramipexole is proved
to be the most potent neuroprotective agent identified till date against MPTP and 6-OHDAinduced toxicity in mice and primates.51a Recent studies showed that pramipexole and talipexole
can prevent L-dopa induced neurotoxicity in mesencephalic cultures and by MPP+ in
neuroblastoma cell line SH-SY5Y.53,54 In terminally differentiated SH-SY5Y cells, in which
both D2 and D3 receptors are expressed, pretreatment with pramipexole demonstrated: (1)
neuroprotective property with pretreatment; (2) the neuroprotection is not due to antioxidant
properties; (3) neuroprotection is not mediated through Dopamine active transporter (DAT) and
(4) neuroprotection occurs via D2/D3 receptor-mediated mechanisms. It has been suggested that
induction of D3 receptor-mediated neuroprotective factors, such as Brain-derived Neurotrophic
factor (BDNF) and Bcl-2, may be responsible for the protective actions of D3-preferring
agonists.55

1.9. Receptor dependent neuroprotection:
Pramipexole was shown to significantly attenuate L-dopa-induced, tyrosine hydroxylase
immunoreactive (THir, a marker for dopamine neurons) cell loss in a dose-dependent fashion
(ED50 = 500 pM). Pramipexole displays antioxidant activity in the micromolar range, a receptormediated mechanism for this neuroprotection has been postulated.56 D3-preferring antagonists
were shown to dose-dependently inhibit the neuroprotective action of pramipexole.55 Together,
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these data suggested that D3 receptor activation is at least partially responsible for the
neuroprotective effects of pramipexole. Interestingly, treatment of primary mesencephalic
cultures with pramipexole was found to reduce the neurotoxicity of L-dopa and increase the
expression of Bcl-X1. Literature evidences suggest that pramipexole, by increasing Bcl-X1
expression, is able to stabilize the mitochondrial transition pore.55 Pramipexole was found to
attenuate TNFα-induced THir cell loss in mesencephalic cultures and also may be able to block
neurodegenerative actions of inflammatory cytokines, in addition to its functions as a D3
receptor-preferring agonist and antioxidant.
An emerging approach in neuroprotection research is that of the endogenous production
of neurotrophic factors. Glial cell derived Neurotrophic factor (GDNF), Brain-derived
Neurotrophic factor (BDNF) and fibroblast growth factor (FGF) have proved in preclinical
studies to promote the survival and growth of DA neurons. Neurotrophic factors are able to
protect DA neurons exposed to neurotoxins such as 6-OHDA and MPP+. The mechanism by
which neurotrophic factors exert their effects is still unclear. Dutta et al. recently developed D264, a D3 receptor-preferring agonist, which showed neuroprotection in two in vivo PD animal
models. D3-selective antagonist, U99194, significantly altered the neuroprotective effects of D264, indicating a significant role for D3 receptors in its neuroprotection.57

1.10. Clinical trials of neuroprotection in PD with dopamine receptor agonists:
The first major neuroprotective clinical trial was the DATATOP study which was
designed to assess the neuroprotective effects of a combination therapy of selegiline and vitamin
E.58 Selegiline, a MAO-B inhibitor, prevents conversion of MPTP to its toxic metabolite MPP+.
Metabolism of DA by MAO-B produces H2O2; which in the presence of an iron-rich
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environment of substantia nigra produces hydroxyl radical and causes oxidative stress. The time
period until patients required L-dopa treatment was compared in each group. It was found that
combination therapy significantly delayed the initiation of L-dopa treatment. Another study was
carried out to assess the potential neuroprotective effects of selegiline where untreated PD
patients were given selegiline along with a symptomatic dopaminergic agent. The outcome
proved seligiline to be neuroprotective. As there is a reduction in mitochondrial complex I level
in PD, coenzyme Q10 was also used in clinical studies to see if it has neuroprotective effects.
The outcome of this study showed neuroprotective effect of this drug. Clinical trial has also been
undertaken on Ropinirole and Pramipexole. In this study, patients were treated with either
dopamine agonist or L-dopa. The end point determination of this study was challenging because
of the intervention of the symptomatic effect of the drugs. After careful interpretation of the
results using various techniques including single photon emission tomography etc, it has been
found that dopamine agonists are neuroprotective, though some limitations in this study apply.59
PD therapy such as L-Dopa provides symptomatic treatment which gives relief to
patients and neuroprotective therapy should provide delay in disease progression. Currently,
there is no therapy that can either stop the disease progression or restore the functioning of
dopaminergic neuronal system. As PD is a multi-factorial disease involving complex events in
its pathogenesis/progression, PD treatment can either include combination of drugs that act on
different pathological targets (polypharmacology) or a single drug can be designed to possess the
ability to act on multiple pathological targets.60 Drugs which possess the ability to act on
multiple pathological targets, can potentially provide disease-modifying effect, which is highly
desirable to prevent or slow down the progression of PD. Currently, there is no drug in the
market that was designed to aim at multiple pathological factors in PD. However, some
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clinically used drugs have shown potential to possess ability to act on multiple pathological
targets. Pramipexole and Rasagiline have been shown to possess some neuroprotective property
in addition to their dopamine receptor agonist and MAO-B inhibition property, respectively.61
Rasagiline, shown to be neuroprotective, also possesses neurorestorative property in MPTP and
lactacystin-induced degeneration of nigrostriatal dopaminergic neurons.62 Rasagiline is the only
drug that may possess disease-modifying activity as shown by clinical trials.63 Thus, it seems
more appealing to design drugs that aim at multiple pathological targets involved in PD. In fact,
Youdim et. al., designed some structurally modified moieties based on Rasagiline (MAO-B
inhibitor), which possess significant disease-modifying activities in animal models of PD.64 As
iron accumulation has been shown to be critical in pathogenesis of PD, it is ideal to design drugs
with iron-chelator property. Other pathological targets that can be aimed at include COMT,
dopamine receptors, α-synuclein aggregration modifiers and anti-oxidants.
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CHAPTER 2
PREVIOUS WORK ON D-264 AND PRODRUG APPROACH

2.1. Background research on development of our hybrid template
In an effort to design ligands that are selective agonist for the Dopamine D3 receptor as
well as potent non-seletive D2/D3, our group has developed a hybrid structure approach.65 This
involves joining amino tetralin fragments with aryl piperazine fragments by a methylene
linker to generate o u r hybrid template molecule (Fig. 10). The rationale behind such a
design is that the amino tetralin moiety (derived from 5- or 7-OHDPAT) would impart agonist
activity along with some D3 selectivity, while the aryl piperazine moiety (derived from D3
antagonists) would give D3 selectivity by interaction with accessory binding sites that are
different in D3 than D2.4 5

Figure 10. Hybrid Template Approach.

The first lead compound obtained using this hydrid design is D - 7 4 (Figure 11). The
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D2/D3 binding data of this compound showed that it was comparable to 7-OHDPAT in
terms of potency for both D2 and D3 receptors, and in terms of D2/D3 selectivity (Table 2 . 1).
This racemic compound was then resolved into its enantiomers and re-evaluated for
binding affinity. The most active isomer (+)-1 was subsequently evaluated for its
functional activity using the [3H] thymidine incorporation assay, and was found to be a
full agonist in contrast to 7-OHDPAT which is a partial agonist (Table 2.1). This data
showed that compounds derived from our hybrid template can be both selective and potent
ligands for dopamine D3 receptors and also demonstrate full agonist properties for the D3
receptor.

N
HO

N

N
D-74

Figure 11. D-74 - First lead compound using hybrid structure approach.

Table 2.1. Binding data for compound D-74.
Compound

Ki (nM) D2L

Ki (nM) D3

D2L/D3

7-OHDPAT

202 ± 34

2.35 ± 0.29

86

(±)- D-74

142 ± 23

1.56 ± 0.36

91

(-)- D-74

809 ± 65

38.6 ± 0.7
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(+)- D-74

40.6 ± 3.6

1.77 ± 0.42
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Various other compounds were synthesized using this hybrid molecular template
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approach by changing the linker length, position of hydroxyl group and type of arylpiperazine
moiety (Figure 12).
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Figure 12. Additional hybrid compounds.

Table 2.2. Binding Data for Hybrid Compounds

Compound

Ki for D2(nM)

Ki for D3(nM)

D2/D3 (Ratio)

(-)-A

26.0 ± 7.5

0.825 ± 0.136

31.5

(+)-A

238 ± 14

18.4 ± 1.0

12.9

Rac B

219 ± 30

72.2 ± 17.2

3

(-)-C

243 ± 65

4.15 ± 0.76

58.6

(+)-C

1,979 ± 567

44.0 ± 10.6

45

(-)-D / D-264

234 ± 40

0.925 ± 0.234

253
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2.2. Previous work on D-264
D-264 showed high selectivity for D3 receptors in the binding data. The in-vitro binding
assay is a competition assay that determines the inhibition constants of the compounds for
displacing the binding of dopamine receptor antagonist [3H]-Spiperone at the cloned hD2L and
D3 receptors expressed in HEK-293 cells.
After this, functional potency studies were conducted (Table 2.3). The functional assay
measures quantitatively the ability of the compound to stimulate the receptor to initiate
downstream events. The maximum stimulation of a particular receptor produced by the
compound compared to the reference compound i.e., dopamine (which is considered to be full
agonist and produce 100% maximum stimulation) is represented by Emax. The maximum
stimulatory potency (Emax) determines if the compound is full agonist, partial agonist or
antagonist compared to dopamine which is considered to be a full agonist. The concentration of
the compound that produces half maximal response (EC50) determines the affinity of the
compound towards the high affinity state of the receptor. In this assay, amount of binding of
non-hydrolyzable analog of GTP ([35S]GTPγS) to the α-subunit of heterotrimeric G-protein was
measured and compared with the reference dopamine which was considered to be 100 % agonist
for both the receptors. The assays were carried out with cloned human D2 and D3 receptors
expressed in CHO cells.
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Table 2.3. Stimulation of [35S]GTPγS binding to hD2 and hD3 receptors expressed in CHO cells
for D-264
CHO-D2
Compound

EC50 (nM)a

CHO-D3
%Emax

[35S]GTPãS
(-)-D-264

33.1 ± 6.6

EC50 (nM)a

%Emax

D2/D3

90 ± 4.3

22

[35S]GTPãS
104 ± 5

1.51 ± 0.02

Further ahead, the novel D3 receptor-preferring agonist D-264 was evaluated to
determine BDNF and GDNF levels in MPTP- and Lactacystin-lesioned mice.57 Neuroprotection
against MPP+ and in-vivo blood brain barrier crossing ability of D-264 by reversal of reserpineinduced hypolocomotion were also evaluated.66

2.2.1. Effect of D-264 on Brain Derived Neurotrophic Factor (BDNF) and Glial-cell
Derived Neurotrophic Factor (GDNF) levels in MPTP- and Lactacystin-lesioned mice
MPTP or lactacystin administration showed a decrease in expression of BDNF by 23.9%
and 24.7% and decrease of GDNF by 55.0% and 30.5%, respectively (Figure 13). D-264
pretreatment with low and high (1mg/kg and 5mg/kg respectively) doses attenuated the
reduction of BDNF by 6.7% and 60.0% in MPTP-lesioned mice, respectively (Figure 13a).
Further, pretreatment with low and high doses of D-264 attenuated the reduction of BDNF by
31.3% and 50.2%, respectively, in lactacystin-lesioned mice (Figure 13b). D-264 pretreatment
with low and high doses attenuated the reduction of GDNF by 32.4% and 92.7% respectively, in
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MPTP-lesioned mice, and in lactacystin-lesioned mice, increased the level of GDNF by 150%
and 160%.57 (Figure 13)

Figure 13. Effects of pretreatment with D-264 on expression of BDNF and GDNF proteins in the
striatum in MPTP- and Lactacystin-induced mice. D-264 at two doses: 1 mg/ kg (low) and 5 mg/
kg (high).57

2.2.2. In vitro Neuroprotection against MPP+ toxicity
Previously, dose-dependent experiment with neurotoxin MPP+ was conducted. 100 μM
of MPP+ was chosen as it induced 50-60% cell death. To test whether D-264 can protect
dopaminergic MN9D cells from MPP+ induced toxicity, the cells were pre-treated with various
concentrations of (20, 10, 5, 1, 0.1, 0.01 and 0.001 μM) of D-264 for 1h and then co-treated with
100 μM MPP+ for an additional 24h. The dose dependent effect of treatment of D-264 in
reversing the toxicity of MPP+ to dopaminergic MN9D cells is demonstrated in Figure 14. The
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data from the MTT assay further indicated that D-264 can protect the MN9D cells in a dosedependent manner. Significant protection from toxicity of MPP+ was conferred by 5, 10 and 20
μM doses which showed approximately 20%, 40% and 20% neuroprotection respectively.66

Figure 14. Dose dependent effect of combination of pretreatment followed by co-treatment of D264 with 100 μM MPP+ on cell viability of MN9D cells from toxicity of 100 μM MPP+. A:
MN9D cells were pretreated with different doses of D-264 for 1 h followed by co-treatment with
100 μM MPP+ for 24 h. The values shown are means ± SDs of three independent experiments
performed in 4-6 replicates.66

2.2.3. Evaluation of In vivo Blood Brain Barrier Crossing Ability of D-264 by Reversal of
Reserpine Induced Hypolocomotion in Rats
Reserpine causes a cataleptic condition in rats due to depletion of catecholamine.67 This
is a well established model for PD. Inhibition of locomotion in rats was observed 18 h after the
subcutaneous administration of 5 mg/kg reserpine by the development of akinesia in rats. D-264
at dose (5 µMol/kg, i.p., DI water) failed to produce any significant effect in reversing akinesia
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in the reserpine treated rats (Figure 15). However, D-264 was more effective when it was
dissolved in 10% beta-hydroxy cyclodextrin solution. It is evident from the result that D-264
could not efficiently cross the blood brain barrier whereas if dissolved in 10% beta-hydroxy
propyl cyclodextrin solution was able to cross blood-brain barrier and produced in vivo activity
(Figure 15).66

Figure 15. Effect of D-264 upon reserpine (5.0 mg/ Kg, s.c.)-induced hypolocomotion in rats.
Data are means ± S.E.M, n = 4 per value. The plots are the representation of horizontal
locomotor activity at discrete 30-min intervals after the administration D-264 (i.p.) at the dose of
5 µMol/ kg compared to control reserpine treated rats in 18h post reserpine treatment.66

2.3. Prodrug approach
As it was evident from the Figure 16, D-264 could not efficiently cross the BBB,
however, it did cross the BBB to produce in vivo activity when dissolved in 10% beta-hydroxy
propyl cyclodextrin solution.
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In order to deliver D-264 more efficiently into the brain, we decided to design a prodrug
(Compound 8, Scheme 3).

N
NH
N
N

N

S

O
NH

S
O

8
Parent D-264

Modified cysteine

Figure 16. Prodrug design template

This prodrug consists of a cysteine moiety attached to D-264 by an amide bond which we
hypothesized would, be cleaved to release the parent neuroprotective D-264 after crossing the
BBB. The hydrolytic clevage to release the parent D-264 and L-cystine should be accomplished
by amidases which are present abundantly in the brain. A substantial amount of research points
out the important role of antioxidants such as L-cysteine in reducing the oxidative stress
associated with PD and increasing the endogenous GSH and other antioxidant concentrations in
PD patients.68 It is known that extracellular L-cysteine is taken up by astrocytes; which provide
biochemical support to the endothelial cells which form the BBB. This L-cysteine, along with Lglutamic acid and glycine are used to synthesize glutathione. Presumably, this prodrug should be
able to deliver D3 agonist activity (from D-264) and antioxidant property (from cysteine
moeity).
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CHAPTER 3
HYPOTHESIS AND SPECIFIC AIMS

Parkinson’s disease is a progressive neurodegenerative disease that results in loss of
dopaminergic neurons in the substantia nigra. The major symptoms of the disorder are tremors
at rest, bradykinesia, and rigidity. Degeneration of DA-generating neurons in the SNPc
region of the brain causes a subsequent reduction in DA level in the striatum. Currently, LDOPA therapy in PD produces only symptomatic relief. However, prolonged use of L-DOPA
leads to major side effects such as dyskinesia and severe wearing off symptoms.36 Therefore,
new strategies are needed which should include combination of neuroprotection treatment along
with providing symptomatic relief.
In our on-going drug discovery studies, we have developed a library of D2/D3 agonist
molecules in which D-264 was found to be one of the potent D3 preferring agonist. D-264; a D3preferring agonist proved to show very potent neuroprotection in two animal models.57 Although,
it showed good D3-preferring and neuroprotection, it proved to be less efficient in brain
penetration. A substantial amount of research points out the very important role of
antioxidants such as L-cyteine in reducing the oxidative stress associated with PD and increasing
the endogenous GSH and other antioxidant concentrations in PD patients.68 The well-known
antioxidant property of L-cysteine and its role in the glutathione synthesis suggests that Lcysteine based prodrugs with D2/D3 agonist may possess therapeutic potential. As the astrocytes
in the blood brain barrier take up extracellular L-cysteine and transports it to the neurons, we
assumed L-cysteine intermediate would be an ideal moiety to conjugate with D-264 to design the
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prodrug. Presumably, this prodrug would be able to impart efficient BBB penetration,
neuroprotection with antioxidant property.

3.1 General Aims:
In our continued efforts to design and develop novel ligands with high affinity for both D2,
D3 receptors with preferential selectivity for the D3 receptor, we have adopted a ‘hybrid
structure approach’. Our goal is to develop drugs that provide symptomatic and
neuroprotective therapy of Parkinson’s disease. Thus, neuroprotective parent compound
containing additional L-cysteine moiety should improve brain penetration of the parent D3
agonist. We thus developed bi-functional prodrug by incorporating antioxidant L-cysteine
with one of our potent D3 agonist molecule which has free radical scavenging and endogenous
antioxidant regenerating capacity that will give neuroprotection by reducing oxidative stress
and by increasing the concentration of GSH in the parkinsonian brain.

3.2 Specific Aims:
3.2.1

Ligand design and synthesis:
Our aim is to explore D-264 with preferential selectivity for D3 receptors, and

synthesize a L-cysteine derived prodrug having additional anti-oxidant property. The prodrug
would have D3 agonist properties to provide not only symptomatic relief but also
neuroprotection effect. Before synthesizing prodrug of D-264, we propose to synthesize a model
prodrug with similar structural identity and perform the hydrolysis experiment. We hypothesize
that the behavior of the model prodrug will correlate to the prodrug of D-264.
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3.2.1.1

Modification by addition of L-cysteine to the amine of 4,5,6,7-Tetrahydrobenzothiazol-2-ylamine ring of D-264 moiety of the molecule:
We plan to synthesize a compound that contains L-cysteine at the amine end of the

4,5,6,7-tetrahydrobenzothiazol-2-ylamine ring of D-264 molecule. D-264 exhibited potent
neuroprotection but showed less efficiency in BBB penetration by itself. Based on literature
evidence, it is assumed that the presence of L-cysteine moiety would provide efficient blood
brain barrier penetration. It is known that extracellular L-cysteine is taken up by the astrocytes;
which provide biochemical support to the endothelial cells that form the BBB. Amino acids
such as L-cysteine, L-glutamic acid and glycine are used to synthesize glutathione.69 Hence, the
prodrug of D-264 would help allow D-264 to cross the BBB more efficiently along with
additional anti-oxidant property with L-cysteine. Such an effect should provide synergy in
neuroprotection.

3.2.2

Specific aim for in vitro hydrolysis experiment:
The enzymatic stability of the synthesized prodrug molecule will be studied to

evaluate its stability and sensitivity in undergoing enzymatic cleavage in rat plasma, brain
homogenate and brain supernatant to regenerate the parent drug, D-264.

3.2.3

Specific aim for in vivo brain penetration experiment:
The ability of penetration of the synthesized prodrug molecule will be studied by

determination of concentration of prodrug in brain supernatant over a period of time (0-48 h).
The concentration of prodrug and the parent drug, D-264 cleaved from its prodrug will be
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compared to evaluate the BBB crossing efficiency over a certain period of time.

3.2.4. Biochemical antioxidant assay:
D-264, prodrug, cyclized Cysteine (chemical moiety conjugated to prodrug with
modification of L-Cysteine) and L-Cysteine (known anti-oxidant as a positive standard) will be
tested in a biochemical colorimetric antioxidant assay, known as DPPH assay.

3.3

Our hypothesis:
In our study, we hypothesize that the proposed prodrug approach will be able to provide in

vitro hydrolysis in brain homogenate/supernatant without being prematurely cleaved in plasma,
and in vivo brain penetration with greater efficiency than the parent drug molecule, D-264
alone. We also hypothesize that introduction of cyclized L-cysteine moiety in the formation of
the prodrug would be able to provide facile entry into the brain compared to the drug itself.
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CHAPTER 4
RESULTS AND DISCUSSION
Our main objective was to design and develop a Cysteine-derived prodrug of D-264 (2Oxo-thiazolidine-4-carboxylic

acid

(6-{[2-(4-biphenyl-4-yl-piperazin-1-yl)-ethyl]-propyl-

amino}-4,5,6,7-tetrahydro-benzothiazol-2-yl)-amide) (Compound 8) that will possess enhanced
blood brain barrier crossing ability compared to the parent D-264. It is expected that prodrug
should get hydrolyzed in the brain to release the parent D-264 along with cysteine, thereby
further increasing efficacy of D-264 with synergizing antioxidant activity. The well-known
antioxidant property of L-cysteine and its role in the glutathione synthesis suggests that Lcysteine based prodrugs with D2/D3 agonist may possess a therapeutic potential for the
treatment of PD. We assumed L-cysteine intermediate would be an ideal moiety to conjugate
with the D-264 to design the prodrug since the astrocytes in the blood brain barrier take up
extracellular L-cysteine and transports it to the neurons. The transported L-cysteine acts as a
source for the glutathione synthesis. It was found that PD patients have low levels of glutathione
and conjugating modified L-Cysteine moiety to D-264 may work as an antioxidant and also
additional source for the glutathione synthesis. To begin with, we synthesized the modified
cysteine intermediate (Compound 1, Scheme 1) and conjugated this intermediate to synthesize a
model prodrug (Compound 2, Scheme 2) in order to develop an efficient synthetic route and test
the degree of hydrolysis by an ex vivo hydrolysis experiment using rat plasma and brain
homogenates. After successfully establishing the synthetic route for prodrug and hydrolysis
experiment, we have synthesized prodrug of D-264 (Compound 8, Scheme 3).

Our next

objective was to carry out an in vivo brain penetration experiment to determine the efficiency of
BBB penetration of prodrug in comparison with D-264. Further, our goal was to evaluate the ex
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vivo hydrolysis of this prodrug to parent D-264 by conducting a hydrolysis experiment in rat
brain homogenate/supernatant and plasma. Our final goal was to carry out DPPH antioxidant
assay to evaluate the antioxidant potency of prodrug and D-264. Therefore, in this chapter, we
will discuss
1) Chemistry involved in synthesizing compounds
a. Modified cysteine intermediate (Compound 1)
b. Model prodrug (Compound 2)
c. D-264 prodrug (Compound 8)
2) Ex vivo hydrolysis experiment involving compound 2
3) Ex vivo hydrolysis experiment involving compound 8
4) In vivo brain penetration experiment involving compound 8
5) DPPH antioxidant assay for compound 8
The procedure followed to do all the above mentioned assays are discussed in detail in the
materials and methods section.

4.1. Chemistry involved in synthesizing compounds:
a. (R)-2-oxothiazolidine-4-carboxylic acid (Compound 1, Scheme 1)
Scheme 1 describes the synthesis of modified cysteine intermediate (1). L-cysteine was
cyclized under strong basic conditions (NaOH) and phenyl chloroformate to yield intermediate
1. This intermediate 1 was used to conjugate to the amine of the thiazolidium ring on the parent
compound.
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Scheme 1
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i. NaOH in water, Phenyl chloroformate, toluene, 25oC for 2h, acidify with conc. HCl (pH 1)

b.

2-Oxo-thiazolidine-4-carboxylic

acid

{6-[propyl-(2,4,6-trimethyl-benzenesulfonyl)-

amino]-4,5,6,7-tetrahydro-benzothiazol-2-yl}-amide(Compound 2, Scheme 2)
Scheme 2 depicts the synthesis compound (±) 2. Intermediate 1 was converted to acid
chloride using oxalyl chloride to yield 1a. Previously synthesized Mst-Pramipexole (±)1b, was
coupled with 1a using triethylamine to yield (±)2.
Scheme 2
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Reagents and conditions:
i. 1b, 1a, DCM, DMF, TEA at 0oC, RT overnight
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c.

2-Oxo-thiazolidine-4-carboxylic

acid

(6-{[2-(4-biphenyl-4-yl-piperazin-1-yl)-ethyl]-

propyl-amino}-4,5,6,7-tetrahydro-benzothiazol-2-yl)-amide (Compound 8, Scheme 3)
In Scheme 3, we describe the synthesis of (-)8. Commercially available 4-Bromobiphenyl together with piperazine was coupled using Palladium (II) acetate catalyst to yield (3).
Amine (3) was then reacted with TBDMS protected 2-bromoethanol (97%) to give 4.
Deprotection of intermediate 4 was carried out using TBAF to yield alcohol (5). Oxidation of the
alcohol (5) by SO3-pyridine, DMSO and triethylamine yielded the aldehyde (6). Aldehyde was
immediately reacted with (-) Pramipexole by reductive amination to yield D-264 (7). The acid
chloride intermediate (1a) was freshly synthesized and coupled with D-264 (7) under basic
conditions (triethylamine) to give D-264 prodrug (-)8.
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Reagents and conditions:
i. Piperazine, Cs2CO3, Pd(OAc)2, BINAP, 80-90oC, Toluene; ii. Br-CH2-CH2-OTBS, K2CO3, ACN, 80-90oC,
overnight; iii. TBAF (tetra butyl ammonium fluoride), THF, 0oC, 3 h; iv. SO3-pyridine, DMSO, DCM, triethylamine,
0oC to RT; v. (+) Pramipexole / (-) Pramipexole, NaBH(OAc)3, DCM; vi. Acyl intermediate 1a, 7 (D-264),
triethylamine, DCM, overnight.

4.2. Ex-vivo hydrolysis experiment involving compound 2 (Scheme 2)
Hydrolysis is defined as the cleavage of chemical bonds by the addition of water. Our
experiment is focused on to observe whether the amide bond in the prodrug would be cleaved by
amidase enzymes present in brain. The detailed experiment procedure is mentioned in the
Materials and Methods section.
As mentioned earlier, the ex vivo hydrolysis experiment by using compound 2 (Scheme
2) was done as a proof of concept study to understand the degree of hydrolysis of the model drug
with respect to time before carrying out synthesis of D-264 prodrug (Compound 8, Scheme 3).
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We observed a gradual increase in cleavage of model prodrug from 0 h to 12 h. Maximum
cleavage percentages were observed at 24 h and 48 h in both plasma and brain. It was observed
that 9% cleavage and 21% cleavage of Model prodrug (compound 2, scheme 2) in rat plasma at
24 h and 48 h, respectively, to yield parent Mst-Pramipexole. (parent compound 1b, Scheme 2)
(See Figure 17)

Figure 17. Ex vivo Hydrolysis experiment data involving Compound 2 (Scheme 2) in plasma
(n=2).
At 24 h and 48 h in rat brain homogenate, we noticed a higher percentage of cleavage
i.e., 33% and 70% respectively, as compared to plasma (See Figure 18) for the model drug.
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Figure 18. Ex vivo Hydrolysis experiment data involving Compound 2 (Scheme 2) in brain
homogenate (n=3).
It was perceived that the availability of enzyme amidase might be reduced in case of
brain homogenate due to presence of tissue, resulting in the lower percentage of hydrolysis. To
overcome this possibility, we used brain supernatant which resulted in higher percent of
cleavage when compared to brain homogenate. At 24 h and 48 h, we noticed a cleavage of 51%
and 86% of (2). (See Figure 19)
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Figure 19. Ex vivo Hydrolysis experiment data involving Compound 2 (Scheme 2) in brain
supernatant (n=2).
The above data helped us to conclude that using brain supernatant instead of brain
homogenate in the hydrolysis experiment would be more efficient due to greater availability of
amidases. In the hydrolysis experiment involving prodrug of D-264, brain supernatant was used
to determine hydrolysis of prodrug in the brain.
These results also gave us an insight that the model prodrug cleaves to a greater
percentage in the rat brain than in the plasma; thereby, preventing loss of prodrug due to
premature cleavage before crossing the BBB.

4.3. Ex vivo hydrolysis experiment involving compound 8 (Scheme 3)
The hydrolysis experiment using model prodrug (Compound 8, Scheme 3) proved that
prodrug cleaves a greater percentage in rat brain than plasma. On the basis of this, after
synthesizing D-264 prodrug (-8), we carried out hydrolysis experiment. The procedure followed
to carry out the hydrolysis experiment is discussed in detail in the materials and methods
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section. From 0 h to 12 h, we observed a gradual increase of cleavage of the prodrug. Maximum
cleavage of prodrug were observed at 24 h and 48 h in plasma and brain, respectively. In rat
plasma, it was noticed that at 24 h and 48 h, there was a cleavage of 8% and 13% of D-264
prodrug (8) to yield D-264 (7). (See Figure 20)

Figure 20. Ex vivo Hydrolysis experiment data involving Compound 8 (Scheme 3) in plasma
(n=3).
Whereas, in the rat brain supernatant at 24 h and 48 h, the hydrolysis of prodrug is 33%
and 57% of (8) to yield parent D-264 (7). (See Figure 21)
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Figure 21. Ex vivo Hydrolysis experiment data involving Compound 8 (Scheme 3) in brain
supernatant (n=3).
These results gave us an insight that D-264 prodrug (Compound 8, Scheme 3) cleaves to
a greater percentage in the rat brain than in plasma; thereby preventing loss of prodrug due to
premature cleavage in the plasma before crossing the BBB.

4.4 In vivo brain penetration experiment involving compound 8 (Scheme 3)
D-264 exhibited potent neuroprotection but showed less efficiency in the BBB
penetration by itself. The in vivo brain penetration experiment was carried out to determine the
efficiency of the BBB penetration between prodrug and D-264. In this experiment, two groups of
rats were injected intraperitoneally; one set was administered D-264 HCl salt and the other
group was treated with the prodrug HCl salt at a dose of 50 µMoL/kg. After a period of 2 h and
4 h, the animal was sacrificed and the plasma and brain tissues were collected. The detailed
experiment procedure is mentioned in the Materials and Methods section.
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The concentration of D-264 and the prodrug (ng), were determined separately using
HPLC analysis. Using the concentrations of D-264 and prodrug in brain, percentage of total drug
penetration to the brain by prodrug and D-264 were calculated and the ratio was determined. We
observed a 7.5-fold increase in brain penetration of prodrug compared to D-264 at 2 h (See
Figure 22, Table 4.1). Whereas, at 4 h, we observed a 5.7-fold increase in brain penetration of
prodrug compared to D-264. (See Figure 23, Table 4.2)
The concentration of prodrug remains fairly similar at 2 h and 4 h; but that of D-264 is
higher at 4 h than at 2 h which in turn results in a lower fold increase ratio at 4 h than that at 2 h.
The possible reason of this increased concentration of D-264 at 4 h can be explained using
Figure 15 under Chapter 2. Under Section 2.2.3, figure 15 depicts almost constant locomotor
activity up to 2 h when D-264 is administered alone. After 2 h, there is a gradual increase in
activity which continues up to 6 h. We assume that increased locomotor activity after 2 h could
be due to delayed availability of D-264 in the brain. Comparing this assumption with the brain
penetration experiment, we can conclude that higher concentration of D-264 at 4 h is due to the
delayed availability of D-264.

45

Figure 22. Brain penetration experiment involving Prodrug (including cleaved D-264) and D264 alone at 2 h (n=3).
Table 4.1. Brain penetration experimental data at 2 h (n=3).
Compound

Average concentration of

Average concentration of

drug In Plasma (ng/mL)

drug in Brain supernatant
(ng/g)

Prodrug + cleaved D-264

10718.7 ng/mL

18998.4 ng/g

D-264

1094.4 ng/mL

2524.8 ng/g

Cleaved D-264

1140.3 ng/mL

2160 ng/g
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Table 4.2. Statistical comparative analysis between prodrug of D-264 and D-264 alone from
brain penetration experiment (2 h).
Compound

Brain:Brain

Plasma:Plasma

Brain:Plasma

Prodrug + cleaved D-

7.5

9.8

-

-

-

1.8

-

-

2.3

264 / D-264 alone
Prodrug + cleaved D264
D-264

Figure 23. Brain penetration experiment involving Prodrug (including cleaved D-264) and D264 alone at 4 h (n=3).
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Table 4.3. Brain penetration experimental data at 4 h (n=3).
Compound

Average concentration of

Average concentration of

drug In Plasma (ng/mL)

drug in Brain supernatant
(ng/g)

Prodrug + cleaved D-264

9007.2 ng/mL

25152 ng/g

D-264

825.6 ng/mL

4416 ng/g

Cleaved D-264

314.4 ng/mL

2236.8 ng/g

Table 4.4. Statistical comparative analysis between prodrug of D-264 and D-264 alone from
brain penetration experiment (4 h).
Compound

Brain:Brain

Plasma:Plasma

Brain:Plasma

Prodrug + cleaved D-

5.7

10.9

-

-

-

2.8

-

-

5.3

264 / D-264 alone
Prodrug + cleaved D264
D-264
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Figure 24. Brain penetration experiment involving detailed individual drug representation at 2 h
and 4 h. (n=3)
In Figure 22 and 23, it is observed that there is an increased concentration of prodrug of
D-264 compared to D-264 alone in plasma. We assume that this could be due to the higher
lipophillicity of D-264 compared to prodrug of D-264 which delays it from entering the systemic
circulation or makes it more susceptible to binding with proteins. (LogPprodrug = 5.67, LogPD-264
= 6.05)
From the results of this experiment, it is evident that the prodrug crosses the BBB into
the brain more efficiently than D-264.

4.5. DPPH antioxidant assay for compound 8
Oxidative stress has been strongly implicated in PD pathogenesis. One of our objectives
while designing the D-264 prodrug, was to impart additional antioxidant activity by conjugating
cysteine moiety. Antioxidants such as L-cysteine shows reduction of the oxidative stress
associated with PD and increases the endogenous GSH and other antioxidant concentrations in
PD patients.68 Scavenging of DPPH (1,1-diphenyl-2-picrylhydrazyl) radical by D-264 (-)7, D-
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264 prodrug (-)8, modified cysteine intermediate (1) and L-cysteine was carried out (Figure 25).
Generally, antioxidants will react with DPPH (1,1-Diphenyl-2-picrylhydrazyl), which is a
nitrogen-centered radical with a characteristic absorption at 517 nm and gets converted into 1,1,diphenyl-2-picryl hydrazine, due to its hydrogen donating ability at a very rapid rate. The degree
of discoloration indicates the scavenging potentials of the antioxidants. It is known that free
radicals cause auto-oxidation of unsaturated lipids.70 On the other hand, antioxidants are
believed to intercept the free radical chain of oxidation and to donate hydrogen, thereby forming
stable end product, which does not initiate or propagate further oxidation of lipid. As shown in
Figure 25, all compounds except compound 1, inhibited DPPH radical activity dose dependently
over a period of 4 h. Overall, (-)7 exhibited good antioxidant potency. (-)7 and (-)8 showed high
antioxidant activity when compared to standard antioxidant L-cysteine ranging from 20uM160uM. (-)7 showed 79% scavenging activity at 180 µM (4 h) and (-)8 showed 81% scavenging
activity at 180 µM (4 h) which later formed a plateau at 200 µM for both compounds. However,
compared to (-)8; (-)7 showed slightly lesser antioxidant potency. Interestingly, (1) exhibited no
antioxidant activity. The standard antioxidant L-cysteine showed a high antioxidant activity at
180-250 µM (4 h) over compounds (-)7 and (-)8.. These results indicate that antioxidant property
of prodrug is slightly potent when compared to D-264, and conjugation of modified Cysteine is
not affecting its activity. According to our hypothesis, after entry into the brain, prodrug upon
hydrolytic cleavage should yield parent D-264 and L-cysteine molecules. Although it is hard to
establish the complete antioxidant profile of prodrug in cell-free system, it is assumed that the
cleaved cysteine acts as an antioxidant which can be demonstrated by antioxidant assays under
in vivo conditions. Additionally, cysteine also acts as a source in the glutathione synthesis
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which can be proved with additional experiments such as glutathione estimation in rat brain
samples.

Figure 25. DPPH antioxidant assay for compound 8 (Scheme 3) (n=3)
The data obtained revealed that the compounds (-)7 and (-)8 are strong free radical
scavengers and primary antioxidants that react with DPPH radical. We believe that compound ()8 has stronger potential to reduce the oxidative stress in the Parkinsonian brain compared to (-)7
as the conjugated Cysteine moiety gets into action upon cleavage.
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CHAPTER 5
MATERIALS AND METHODS
5.1. Chemistry:
Solvents and reagents were obtained from commercial suppliers and used as received
unless otherwise indicated. Dry solvents were obtained according to the standard procedure as
described in Vogel’s book on practical organic chemistry. Analytical silica gel-coated TLC
plates (Silica Gel 60 F254) were purchased from EM Science and were visualized with UV light
or by treatment with phosphomolybdic acid (PMA), ninhydrin and potassium permanganate
(KMn04) solution. Flash chromatography was carried out on Davisil Chromatographic silica
media 40-63 micron. 1H &

13

C NMR spectra were routinely obtained on Varian 400 MHz and

600 MHz FT NMR. The NMR solvents used were CDCl3, DMSO or CD3OD as indicated are
obtained from Cambridge Isotope Laboratories Inc. TMS was used as an internal standard. Low
resolution Mass spectrometry was performed by Lumigen facilities (Wayne State University,
Chemistry department) using Waters Micromass ZQ and Shimadzu LCMS-8040.

5.1.1 Method involving synthesis of (R)-2-oxothiazolidine-4-carboxylic acid (1):
Whilst cooling with ice, L-cysteine hydrochloride monohydrate (5 g, 31.72 mmol) was
added to a solution of NaOH (5.07 g, 126.88 mmol) in water (25 mL). A solution of phenyl
chloroformate (7.96 mL, 63.44 mmol) in toluene (10 mL) was added drop wise to this mixture at
<30oC. After the mixture had been stirred at 25oC for 2 h, the aqueous layer was separated and
washed with toluene (200 mL) to afford the sodium salt of (R)-2-oxothiazolidine-4-carboxylic
acid. The aqueous solution was acidified (pH 1) by adding concentrated HCl and then the
solvent was evaporated in vacuum. The residue was extracted with ethyl acetate (3 x 50mL). The
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combined extracts were evaporated and the solid that formed was collected and recrystallized
from water to afford 1 as colorless crystals (3.22g, 68.8%).71
1H NMR (400 MHz, DMSO-d6): δ 3.46 (dd, J=3.6, 11.4Hz, 1H), 3.72 (dd, J=9.2, 11.4 Hz, 1H),
4.40 (ddd, J=1.3, 3.3, 8.6 Hz, 1H), 8.45 (s, 1H), 8.45 (s, 1H),
13C NMR (100 MHz, DMSO-d6): δ 32.1 (s), 55.8 (d), 172.9 (s), 173.5 (s), (t)

5.1.2. Method involving synthesis of 2-Oxo-thiazolidine-4-carboxylic acid {6-[propyl-(2,4,6trimethyl-benzenesulfonyl)-amino]-4,5,6,7-tetrahydro-benzothiazol-2-yl}-amide (2)
(i) In to a solution of 1 (0.2 g, 1.359 mmol) in CH2Cl2 (10 mL), add few drops of DMF and
then add oxalyl chloride (0.14 mL, 1.6308 mmol) at 0oC. Continue stirring at 0oC for
10 min and then at room temperature for 2h. Monitor for completion of reaction by
TLC. Evaporate the excess oxalyl chloride and solvent. Wash with CH2Cl2 (3 x
50mL) and remove solvent by rotavap to dryness.
(ii) Dissolve acylated modified cysteine (1a) (0.225 g, 1.358 mmol) in CH2Cl2 (10 mL)
with an attached anhydrous CaCl2 guard tube. Mst-Pramipexole (1b) (0.48 g, 1.22
mmol) and triethylamine (1.52 mL, 10.86 mmol) were added at 0oC and the mixture
was kept for stirring overnight at rt. The reaction mixture was quenched by water and
extracted with CH2Cl2 (3 × 100 mL). The combined organic layer was dried using
anhydrous sodium sulfate, filtered and the solvent was removed under reduced
pressure.

The

crude

product

was

purified

by

column

chromatography

(EtOAc/Hexane, 7:3) to give compound 2 (0.135 g, 20%).
1

H NMR (400 MHz, CDCl3): δ 0.74-0.82 (t, 3H, 7.2 Hz), 1.22-1.26 (s, 1H), 1.4-1.6 (m, 2H),

1.88-2 (m, 1H), 2.02-2.1 (m, 1H), 2.26-2.3 (m, 3H), 2.54-2.7 (m, 7H), 2.7-2.9 (m, 3H), 3.02-3.06
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(m, 2H) 3.06-3.12 (m, 1H), 3.12-3.26 (m, 1H), 3.9-4 (m, 1H), 6.92-6.98 (s, 2H), 7.26–7.28 (s,
1H), 8.22-8.26 (s, 1H).
13

C NMR (100 MHz, CDCl3): δ 11.54, 20.96, 22.84, 24.2, 26.21 (2C), 27.72, 27.94, 34.96,

40.86, 45.27, 53.87, 119.27, 132.03 (2C), 140.07 (2C), 142.45, 143.97, 150.05, 155.56, 172.89,
177.49.

5.1.3 Methods involving synthesis of 2-Oxo-thiazolidine-4-carboxylic acid (6-{[2-(4biphenyl-4-yl-piperazin-1-yl)-ethyl]-propyl-amino}-4,5,6,7-tetrahydro-benzothiazol-2-yl)amide
Synthesis of 1-Biphenyl-4-yl-piperazine (3).
A mixture of 4-Bromo-biphenyl (2g, 8.58 mmol), Piperazine (2.2g, 25.74 mmol) were
added to a 250ml RBF and flushed with N2. Palladium (II) acetate (0.088g, 0.4 mmol), BINAP
(0.4g, 0.64 mmol) and Cs2CO3 (7.8g, 24 mmol) were then added. The mixture was added with
50-60mL of anhydrous toluene. Flush the reflux condenser with N2 and connect RBF. The
reaction mixture was stirred continuously at 110oC for 12h. Reaction was monitored by TLC and
on completion, it was allowed to come to room temperature and then CH2Cl2 was added
followed by Celite filtration. Filtrate was concentrated to dryness and water-CH2Cl2 workup was
done and the combined organic extracts were dried over anhydrous sodium sulfate, filtered, and
evaporated. The crude residue was used for next step without purification. (1.92g, 94%).
1

H NMR (600 MHz, CDCl3): δ 1.65-1.75 (bs, 1H, NH) 3.05 (t, 4H, J = 5 Hz), 3.20 (t, 4H, J = 4.8

Hz), 6.99–7.01 (d, 2H, J = 9 Hz), 7.26–7.30 (m, 1H), 7.40 (t, 2H, J = 7.8 Hz), 7.51–7.57 (m, 4H).
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Synthesis of 1-Biphenyl-4-yl-4-[2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-piperazine (4).
A mixture of compound 3 (1g, 4.2 mmol), Potassium carbonate (1.74g, 12.6 mmol), BrCH2-CH2-OTBS (1.1g, 4.62 mmol) in anhydrous acetonitrile (25 mL) was refluxed for 12h.
Reaction was monitored by TLC and on completion, it was allowed to come to room
temperature followed by filtration. Filtrate was concentrated to dryness followed by extraction
with ethyl acetate. The crude product was purified by Silica-gel column chromatography
(EtOAc/Hexane 3:1) to yield compound 4. (0.74g, 44.5%)
1H NMR (600 MHz, CDCl3) δ ppm 0.08-0.1 (t, 6H, J= 3), 0.88-0.92 (t, 9H, J= 3), 2.61-2.64 (t,
2H, J= 5.4 Hz), 2.68-2.72 (t, 4H, J = 4.8 Hz), 3.24-3.28 (t, 4H, J = 5.4 Hz), 3.66-3.68 (t, 2H, J =
5.4 Hz), 6.99–7.01 (d, 2H, J = 9 Hz), 7.26–7.30 (m, 1H), 7.40 (t, 2H, J = 7.8 Hz), 7.51–7.57 (m,
4H).

Synthesis of 2-(4-Biphenyl-4-yl-piperazin-1-yl)-ethanol (5).
Intermediate 4 was dissolved (0.74 g, 1.87 mmol) in THF (15 mL) and kept at 0oC. Tetra
butyl ammonium fluoride (TBAF) (1.1 mL, 3.74 mmol) was added dropwise. After addition,
stirring was continued at room temperature for 3-4 h. THF was evaporated and water-CH2Cl2
workup was done and the combined organic extracts were dried over anhydrous sodium sulfate,
filtered, and evaporated. The crude residue was purified by Silica-gel column chromatography
(MeOH/CH2Cl2 1:9) to afford compound 5 (0.5 g, 52.8%).
1H NMR (600 MHz, CDCl3) δ ppm 2.61-2.64 (t, 2H, J= 5.4 Hz), 2.68-2.72 (t, 4H, J = 4.8 Hz),
3.24-3.28 (t, 4H, J = 5.4 Hz), 3.66-3.68 (t, 2H, J = 5.4 Hz), 6.99–7.01 (d, 2H, J = 9 Hz), 7.26–
7.30 (m, 1H), 7.40 (t, 2H, J = 7.8 Hz), 7.51–7.57 (m, 4H).
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Synthesis of (4-Biphenyl-4-yl-piperazin-1-yl)-acetaldehyde (6).
Into a stirring solution of 5 (0.3 g, 1.06 mmol) in dry CH2Cl2 (5 mL) and DMSO (2 mL)
at room temperature was added Et3N (Triethylamine) (1.48 mL, 10.6 mmol). The reaction
mixture was stirred for 5 min, followed by addition of SO3-pyridine (0.843 g, 5.3 mmol) at 0oC
and was further stirred continuously at the room temperature for 2 h, monitoring by TLC for
reaction completion. The reaction mixture was quenched by water and extracted with CH2Cl2 (3
× 100 mL). The combined organic layer was dried using anhydrous sodium sulphate, filtered and
the solvent was removed under reduced pressure. The crude product was purified by silica gel
column chromatography (EtOAc/MeOH, 9:1) to give compound 6 (0.27 g, 91 %).
1H NMR (400 MHz, CDCl3) δ ppm 2.68-2.8 (t, 4H, J= 4.8 Hz), 3.24-3.3 (s, 2H), 3.3-3.4 (t, 4H,
J = 4.8 Hz), 6.94–7.04 (d, 2H, J = 8.8 Hz), 7.24–7.34 (m, 1H), 7.36-7.46 (t, 2H, J = 8 Hz), 7.5–
7.6 (m, 4H), 9.78 (s, 1H).

Synthesis of N6-[2-(4-Biphenyl-4-yl-piperazin-1-yl)-ethyl]-N6-propyl-4,5,6,7-tetrahydrobenzothiazole-2,6-diamine (7).
Dissolve compound 6 in dry CH2Cl2 (5 mL) and add (+) Pramipexole (0.182 g, 0.864
mmol). After the mixture was stirred for 1 h, NaBH(OAc)3 (0.405 g, 1.92 mmol) was added
portion wise and the mixture was stirred for 48 h at room temperature. The reaction mixture was
quenched with a saturated solution of NaHCO3 at 0 °C and extracted with dicholoromethane (3 ×
100 mL). The combined organic layer was dried over Na2SO4, and the solvent was removed
under reduced pressure. Crude product was purified by Silica-gel column chromatography
(EtOAc/MeOH, 80:20) to give compound 7 (0.2 g, 48 %).72
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1

H NMR (600 MHz, CDCl3): δ ppm 0.86-0.9 (t, 3H, 7.4 Hz), 1.42-1.52 (m, 2H), 1.68-1.76 (m,

1H), 1.98-2.04 (m, 1H), 2.48-2.58 (m, 7H), 2.66-2.76 (m, 7H), 3.02-3.1 (s, 1H), 3.22-3.28 (t, 4H,
J = 5.4 Hz), 6.96–7.0 (d, 2H, J = 9 Hz), 7.26–7.285 (m, 1H), 7.36-7.4 (t, 2H, J = 7.8 Hz), 7.48–
7.56 (m, 4H).

Synthesis of 2-Oxo-thiazolidine-4-carboxylic acid (6-{[2-(4-biphenyl-4-yl-piperazin-1-yl)ethyl]-propyl-amino}-4,5,6,7-tetrahydro-benzothiazol-2-yl)-amide (8).
(i) To a solution of 1 (0.05 g, 0.339 mmol) in CH2Cl2 (5 mL), add few drops of DMF and
then add oxalyl chloride (0.035 mL, 0.407 mmol) at 0oC. Continue stirring at 0oC for
10mins and then at room temperature for 2h. Monitor for completion of reaction by
TLC. Evaporate the excess oxalyl chloride and solvent. Wash with CH2Cl2 (3 x
20mL) and remove solvent by rotavap to dryness.
(ii) Dissolve acylated modified cysteine (0.035 g, 0.21 mmol) in CH2Cl2 (5 mL). Attach a
CaCl2 bent tube. Compound 7 (0.05 g, 0.105 mmol) and triethylamine (0.117 mL,
0.84 mmol) were added and the mixture was kept for stirring overnight. The reaction
mixture was quenched by water and extracted with CH2Cl2 (3 × 50 mL). The
combined organic layer was dried using anhydrous sodium sulfate, filtered and the
solvent was removed under reduced pressure. The crude product was purified by
preparative thin layer chromatography (CH2Cl2/MeOH, 9.5:0.5) to give compound 8
(0.015 g, 23%).
1

H NMR (600 MHz, CDCl3): δ ppm 0.86-0.9 (t, 3H, 7.2 Hz), 1.42-1.52 (m, 2H), 1.7-1.78 (m,

1H), 1.98-2.04 (m, 1H), 2.48-2.58 (m, 7H), 2.66-2.76 (m, 7H), 3.02-3.1 (s, 1H), 3.02-3.06 (m,
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4H) 3.22-3.28 (t, 4H, J = 5.4 Hz), 6.96–7.0 (d, 2H, J = 9 Hz), 7.26–7.285 (m, 1H), 7.36-7.4 (t,
2H, J = 7.8 Hz), 7.48–7.56 (m, 4H), 8.1 (s, 1H).
13

C NMR (150 MHz, CDCl3): δ 11.82, 22.36, 25.51, 29.69, 40.63 (2C), 48.4, 48.84, 53.71 (2C),

58.06 (2C), 58.72, 115.97 (2C), 120.94, 126.37, 126.49 (2C), 127.7 (2C), 128.65 (2C), 132.18,
140.89, 145.91, 150.53, 154.89, 172.19.

5.2. Biology:
5.2.1. Bioreagents:
5.2.1.1 Preparation of 0.02M Phosphate buffer solution:
In the preparation of 0.02M Phosphate buffer solution, Sodium phosphate dibasic
anhydrous (Aldrich), Sodium chloride (Fischer Scientific), Sodium phosphate monobasic
monohydrate (Fisher Scientific) and deionized water were used.
Step 1: Preparation of stock solutions:
Stock solution 1 was prepared using anhydrous sodium phosphate (dibasic) 1.42 g and
sodium chloride 4.25 g in 50mL of DI water. Stock solution 2 was prepared using sodium
phosphate (monobasic) monohydrate 276 mg and sodium chloride 850 mg in 10mL of DI water.
Step 2: Preparation of diluted/secondary stock solutions
1:10 dilutions to each stock solution were made.25mL of stock solution 1 was diluted
with 225mL DI water to give 250mL (~pH = 8.2). 5mL of stock solution 2 was diluted with
45mL DI water to give 50mL (~pH = 5.6).
Step 3: Preparation of 0.02M Phosphate buffer solution pH 7.2-7.4
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250mL of secondary stock solution 1 was taken and 32.5mL of secondary stock solution
2 was added (Both stock solutions used here are from Step 2). pH was checked using Oakton pH
510 series (Eutech instruments) and adjusted to pH 7.2-7.4.

5.2.2. Other Bioreagents:
All HPLC grade solvents used in the preparation of mobile phase for HPLC analysis in
hydrolysis and brain penetration experiments were obtained from Fischer Scientific. HPLC
solvents were filtered using Whatman nylon membrane filters (0.45µm) before use. Small
amounts of formic acid (Sigma) and trifluoroacetic acid (Oakwood chemicals) 0.1% and 0.05%
respectively were added to the prepared mobile phases. Prepared 0.02M Phosphate buffer
solution was used as a buffering agent to prepare plasma buffer solution and brain
homogenate/supernatant buffer solutions in the hydrolysis and brain penetration experiments.
Dulbecco’s phosphate buffer saline (Sigma) was used as a buffering agent during
homogenization of brain.

5.2.3. Hydrolysis experiment:
Hydrolysis is defined as the cleavage of chemical bonds by the addition of water. Our
experiment is focused on cleaving the amide bond by amidase enzymes present in brain. They
catalyze the hydrolysis of interior peptide bonds in peptide chains. This would yield an amine
and an acid from the amide.
In this experiment, adult rat (Sprague Dawley rat) weighing approximately between 250300 g was sacrificed under CO2. Blood was collected by terminal procedure i.e cardiac puncture
in sodium heparin tube- 6ml. After collecting blood, sodium heparin tubes were gently inverted
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3-4 times for uniform distribution of collected blood throughout the tube to make sure the
anticoagulant mixes with the blood to avoid coagulation process. Blood samples containing
tubes were kept at 4°C before centrifugation. Collected blood was centrifuged at 3000RPM for
30 min at 4oC. Plasma (supernatant) was collected in an Eppendorf and was used immediately
for the hydrolysis experiment.
Brain was also collected from the rat and washed with Dulbecco’s phosphate buffer
saline to rinse off the blood. To prepare brain homogenate, 1 g of brain was diluted in 4 mL of
Dulbecco’s phosphate buffer and homogenized. Homogenization was done using Polytron PT
10-35 (Kinematica AG) in short pulses.

5.2.3.1 Model prodrug (Compound 1, Scheme 2) Hydrolysis Experiment:
i. Preparation of Drug solution:
Model Prodrug (compound 2, scheme 2) was used for initial hydrolysis studies to check
whether the amide bond can be cleaved by amidases present in brain homogenate and plasma.
Prodrug was dissolved in 100 µl of MeOH at a concentration of 20 mg/ 1mL. Drug solution was
prepared fresh on the day of experiment.
ii. Preparation of Plasma buffer solution:
Plasma buffer solution was prepared using 0.02 M phosphate buffer and freshly collected
plasma. Plasma buffer contains 80% volume of plasma diluted with buffer. 1.1 mL of plasma
buffer solution was prepared by adding 220 µL of 0.02M phosphate buffer in 880 µL of plasma
and mixed for uniform concentration. Plasma buffer solution was preheated at 37oC in shaking
water bath for 5 minutes before adding the drug solution.
Dilution of Plasma buffer solution required for Experiment:
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1100 µL plasma buffer solution contains 880 µL plasma and 220 µL 0.02 M Phosphate buffer
solution.

Calculations to prepare 0.2 mg/mL Drug stock solution and adding Plasma buffer solution
(For 9 time points i.e, 0, 2, 4, 6, 8, 10, 12, 24, 48 h):
10 µL of 1 mg in 50 µL drug stock solution (20000 µg/ mL) was taken and added to 990 µL of
plasma buffer solution. From this drug stock solution in plasma buffer solution (200 µg/ mL),
100 µL (200 µg/ mL) at every time point was collected. After collecting 100 µL at each time
point, the Eppendorf with the remaining solution was continued with shaking in water bath until
the next time point. The following sample preparation was carried out:
100 µL of drug stock solution in plasma buffer solution (approx. 200 µg/ mL of drug),
was diluted by adding 500 µL of acetonitrile to precipitate proteins (total volume of the solution
is 600 µL i.e. 6 fold dilution). The 600 µL solution (33.33 µg/mL) was vortexed for 15 min at
1400 rpm and the suspension was clarified by centrifugation at 1800 rpm for 10 min. 150 µL of
supernatant was then collected separately in another Eppendorf microtube and 50 µL of MeOH
was added (1.33 fold dilution). The resulting 200 µL solution (25.06 µg/ mL) was subjected to
centrifugation at 1800 rpm for 10 min and 10 µL (25.06 µg/ mL) of this solution was injected to
HPLC for analysis. [The concentrations specified are just an approximation which was done
prior to the experiment to help determine whether the final solution will be in detectable range].
Dilution of Brain homogenate with buffer solution:
1 gram of brain was homogenized and diluted in 4 ml Phosphate buffer solution.
The brain homogenate was vortexed and half of it was transferred to a 15 ml Eppendorf
tube. The rest was then centrifuged at 3000 RPM for 30 min. The supernatant was collected.
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iii. Preparation of Brain homogenate/supernatant buffer solution:
Brain homogenate/supernatant buffer solution was prepared using 0.02 M phosphate
buffer and freshly collected plasma. Brain homogenate/supernatant buffer contains 80% volume
of brain diluted with buffer. 1.1 mL of brain homogenate/supernatant buffer solution was
prepared by adding 220 µL of 0.02 M phosphate buffer in 880 µL of brain and mixed for
uniform concentration. Brain homogenate/supernatant buffer solution was preheated at 37oC in
shaking water bath for 5 min before adding the drug solution.

Calculations

to

prepare

0.2

mg/mL

Drug

stock

solution

and

adding

Brain

homogenate/supernatant buffer solution (For 9 time points i.e, 0, 2, 4, 6, 8, 10, 12, 24, 48 h):
10 µL of 1 mg in 50 µL drug stock solution (20000 µg/ mL) was taken and added to 990
µL of brain homogenate/supernatant buffer solution. From this drug stock solution in brain
homogenate/supernatant buffer solution (200 µg/ mL), 100 µL (200 µg/ mL) at every time point
was collected. After 100 µL was taken for a specific time point, the Eppendorf was placed in the
shaking water bath until the next time point. Using the Brain homogenate, the following sample
preparation was carried out:
100 µL of drug stock solution in brain homogenate/supernatant buffer solution (approx. 200 µg/
mL of drug), was diluted by adding 500 µL of acetonitrile to precipitate proteins (total volume of
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the solution is 600 µL i.e. 6 fold dilution). The 600 µL solution (33.33 µg/ mL) was vortexed for
15min at 1400 rpm and the suspension was clarified by centrifugation at 1800 rpm for 10 min.
150 µL of supernatant was then collected separately in another Eppendorf microtube and 50 µL
of MeOH was added (1.33 fold dilution). The resulting 200 µL solution (25.06 µg/ mL) was
subjected to centrifugation at 1800 rpm for 10 min and 10 µL (25.06 µg/ mL) of this solution
was injected to HPLC for analysis. [The concentrations specified are just an approximation
which was done prior to the experiment to help determine whether the final solution will be in
detectable range]
The same preparation as above was carried out for Brain supernatant analysis.
After analysis of Brain homogenate and supernatant, it was proven that as the supernatant
contains no presence of brain tissue, there is more accuracy in readings in respect to cleavage by
the amidases present. Hence, the experiments after this were conducted using brain supernatant
only.
HPLC System:
The plasma and brain supernatant samples were collected at every 2 h for 0-12 h and at
24 & 48 h time points as well.

Processed samples were analyzed with HPLC (Waters 2489

Alliance Integrated System) to determine the percentage of Model prodrug (compound 2) and
Mst-pramipexole (1b). Mst-pramipexole would be the resulting amine formed in the process of
hydrolysis of the amide bond in Mst-pramipexole prodrug. HPLC was equipped with reverse
phase-C18 column (Sunfire, 5 µM, 4.6 × 150 mm) and elution mode was isocratic with UV
detection at 254 nm. Mobile phase used was Water: Methanol (50:50) with 0.1% formic acid.
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5.2.3.2 D-264 Prodrug (Compound 8,Scheme 3) Hydrolysis Experiment:
i. Preparation of Drug solution:
D-264 Prodrug HCl salt (compound 2, scheme 2) was used for hydrolysis studies to
check whether the amide bond can be cleaved by amidases present in brain homogenate and
plasma. D-264 Prodrug was dissolved in 100 µl of MeOH at a concentration of 20 mg/ mL. Drug
solution was prepared fresh on the day of experiment.

ii. Preparation of Plasma buffer solution:
Plasma buffer solution was prepared using 0.02 M phosphate buffer and freshly collected
plasma. Plasma buffer contains 80% volume of plasma diluted with buffer. 1.1 mL of plasma
buffer solution was prepared by adding 220 µL of 0.02 M phosphate buffer in 880 µL of plasma
and mixed for uniform concentration. Plasma buffer solution was preheated at 37oC in shaking
water bath for 5 min before adding the drug solution.
Dilution of Plasma buffer solution required for Experiment:
1100 µL plasma buffer solution contains 880 µL plasma and 220 µL 0.02 M Phosphate buffer
solution.

Calculations to prepare 0.2 mg/ mL Drug stock solution and adding Plasma buffer solution
(For 9 time points i.e, 0, 2, 4, 6, 8, 10, 12, 24, 48 h):
10 µL of 1 mg in 50 µL drug stock solution (20000 µg/ mL) was taken and added to 990
µL of plasma buffer solution. From this drug stock solution in plasma buffer solution (200 µg/
mL), 100 µL (200 µg/ mL) at every time point was collected. After 100 µL was taken for a
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specific time point, the Eppendorf was placed in the shaking water bath until the next time point.
The following sample preparation was carried out:100 µL of drug stock solution in plasma buffer solution (approx. 200 µg/ mL of drug),
was diluted by adding 500 µL of acetonitrile to precipitate proteins (total volume of the solution
is 600 µL i.e. 6 fold dilution). The 600 µL solution (33.33 µg/ mL) was vortexed for 15 min at
1400 rpm and the suspension was clarified by centrifugation at 1800 rpm for 10 min. 250 µL of
supernatant was then collected separately in another Eppendorf microtube and evaporated
completely. 100 µL of MeOH was added (2.4 fold dilution). The resulting 100 µL solution
(13.89 µg/ mL) was subjected to centrifugation at 1800 rpm for 10 min and 10 µL (13.89 µg/
mL) of this solution was injected to HPLC for analysis. [The concentrations specified are just an
approximation which was done prior to the experiment to help determine whether the final
solution will be in detectable range]
Dilution of Brain homogenate with buffer solution:
1 gram of brain was homogenized and diluted in 4 ml Phosphate buffer solution.
The brain homogenate was then centrifuged at 3000 RPM for 30 min. The supernatant
was collected.

iii. Preparation of Brain supernatant buffer solution:
Brain homogenate/supernatant buffer solution was prepared using 0.02 M phosphate
buffer and freshly collected plasma. Brain homogenate/supernatant buffer contains 80% volume
of brain diluted with buffer. 1.1 mL of brain homogenate/supernatant buffer solution was
prepared by adding 220 µL of 0.02 M phosphate buffer in 880 µL of brain and mixed for
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uniform concentration. Brain homogenate/supernatant buffer solution was preheated at 37oC in
shaking water bath for 5 min before adding the drug solution.
Calculations to prepare 0.2 mg/ mL Drug stock solution and adding Brain supernatant
buffer solution (For 9 time points i.e, 0, 2, 4, 6, 8, 10, 12, 24, 48 h):
10 µL of 1 mg in 50 µL drug stock solution (20000 µg/ mL) was taken and added to 990
µL of brain homogenate/supernatant buffer solution. From this drug stock solution in brain
homogenate/supernatant buffer solution (200 µg/ mL), 100 µL (200 µg/ mL) at every time point
was collected. After 100 µL was taken for a specific time point, the Eppendorf was placed in the
shaking water bath until the next time point. Using the Brain homogenate, the following sample
preparation was carried out:
100 µL of drug stock solution in brain supernatant buffer solution (approx. 200 µg/ mL
of drug), was diluted by adding 500 µL of acetonitrile to precipitate proteins (total volume of the
solution is 600 µL i.e. 6 fold dilution). The 600 µL solution (33.33 µg/ mL) was vortexed for 15
min at 1400 rpm and the suspension was clarified by centrifugation at 1800 rpm for 10 min. 250
µL of supernatant was then collected separately in another Eppendorf microtube and evaporated
completely. 100 µL of MeOH was added (2.4 fold dilution). The resulting 100 µL solution
(13.89 µg/ mL) was subjected to centrifugation at 1800 rpm for 10 min and 10 µL (13.89µg/
mL) of this solution was injected to HPLC for analysis. [The concentrations specified are just an
approximation which was done prior to the experiment to help determine whether the final
solution will be in detectable range]
HPLC System:
The plasma and brain supernatant samples were collected at every 2 h for 0-12 h and at
24 & 48 h time point as well. Processed samples were analyzed with HPLC (Waters 2489
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Alliance Integrated System) to determine the percentage of D-264 prodrug (compound 8) and D264 (7). D-264 would be the resulting amine formed as a process of hydrolysis of the amide
bond in D-264 prodrug. HPLC was equipped with reverse phase-C18 column (Sunfire, 5 µM,
4.6 × 150 mm) and elution mode was isocratic with UV detection at 254nm. Mobile phase used
was Water: Methanol (60:40) with 0.05% Trifluoroacetic acid.

5.2.4 Brain Penetration Experiment:
D-264 is a potent D2/D3 agonist with neuroprotective properties. It showed
neuroprotection in MPTP- and Lactacystin mouse model of PD.57 However, D-264 was proven
to be less efficient in terms of crossing the blood brain barrier. The basic idea of synthesizing the
prodrug of D264 was increase the efficiency in crossing BBB, to improve bio-availability while
imparting additional neuroprotective properties. In this experiment, two rats were injected
intraperitoneally; one with D-264 HCl salt and the other with the prodrug HCl salt. The injected
dose was 50µM/kg. After a period of 2 hours, the animal was sacrificed and the plasma and
brain were collected in the same way as done in Section 6.2.3. The experiment was also carried
out at a period of 4 hours. Percentage of total drug penetration to the brain by prodrug and D-264
were calculated and the ratio was determined. In order to calculate the percentage of total drug
penetration, the amount of drug in the brain had to be determined. Calibration curves for both D264 and D-264 prodrug were prepared and used. Calculated the ratio of D-264 prodrug and D264 at 2 and 4 hours, a higher ratio would show that the prodrug is more efficient than D-264.
Dilution of Brain homogenate with buffer solution:
1 gram of brain was homogenized and diluted in 4 ml Phosphate buffer solution.
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The brain homogenate was then centrifuged at 3000 RPM for 30 min. The supernatant
was collected. From this, 200 µL was taken in an Eppendorf and the following dilutions were
carried out:
200 µL of drug stock solution in brain supernatant buffer solution (approx. 200 µg/ mL
of drug), was diluted by adding 1000 µL of acetonitrile to precipitate proteins (total volume of
the solution is 1200 µL i.e. 6 fold dilution). The 1200 µL solution (33.33 µg/ mL) was vortexed
for 15 min at 1400 rpm and the suspension was clarified by centrifugation at 1800 rpm for 10
min. 500 µL of supernatant was then collected separately in another Eppendorf microtube and
evaporated completely. 100 µL of MeOH was added (2.4 fold dilution). The resulting 100 µL
solution (13.89 µg/ mL) was subjected to centrifugation at 1800 rpm for 10 min and 10 µL
(13.89 µg/ mL) of this solution was injected to HPLC for analysis. [The concentrations specified
are just an approximation which was done prior to the experiment to help determine whether the
final solution will be in detectable range]

Sample preparation for plasma:
From the collected plasma, 200 µL was taken in an Eppendorf and the following
dilutions were carried out:
200 µL of drug stock solution in plasma buffer solution (approx. 200 µg/ mL of drug),
was diluted by adding 1000 µL of acetonitrile to precipitate proteins (total volume of the
solution is 1200 µL i.e. 6 fold dilution). The 1200 µL solution (33.33 µg/ mL) was vortexed for
15 min at 1400 rpm and the suspension was clarified by centrifugation at 1800 rpm for 10min.
500 µL of supernatant was then collected separately in another Eppendorf microtube and
evaporated completely. 100 µL of MeOH was added (2.4 fold dilution). The resulting 100 µL
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solution (13.89 µg/ mL) was subjected to centrifugation at 1800 rpm for 10 min and 10 µL
(13.89 µg/ mL) of this solution was injected to HPLC for analysis. [The concentrations specified
are just an approximation which was done prior to the experiment to help determine whether the
final solution will be in detectable range]
HPLC System:
HPLC instrument (Waters 2489 Alliance Integrated System) was used to determine the
amount of D-264 prodrug and D-264 (area under curve values were substituted in the calibration
curve to give the amount of drug per 10 µL). The column used was a reverse phase-C18 column
(Sunfire, 5 µM, 4.6 × 150 mm). Elution mode was isocratic with UV detection at 254 nm.
Mobile phase used was Water: Methanol (60:40) with 0.05% trifluoroacetic acid.

5.2.5. Evaluation of Antioxidant Activity by DPPH Radical Scavenging Assay.
The DPPH radical-scavenging effect was measured according to reported method.73 This
method measures hydrogen atom or electron donating activity. DPPH (1,1-Diphenyl-2picrylhydrazyl) is a stable free radical of a purple color which gets reduced to a yellow colored
1,1,-diphenyl-2-picryl hydrazine. Each tested sample was mixed with DPPH radical in methanol
and after 30 min incubation at room temperature (30 oC) in the dark, the absorbance was read at
517 nm.
Assay procedure:
To a 96-well plate, an amount of 100 μL of drug solutions (dissolved in methanol)
ranging from 20 to 250 μM was added. Next 100 μL of 200 μM methanolic solution of DPPH
(1,1-diphenyl-2-picrylhydrazyl) was added and the plate was shaken vigorously at 30 °C for 30
min. Control wells received 100 μL of methanol and 100 μL of 200 μM methanolic DPPH
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solution. Wells containing only 200 μL of methanol served as a background correction. The
change in absorbance of all samples and standard (L-cysteine) was measured at 517 nm. Radical
scavenging activity was expressed as inhibition percentage and was calculated using the
formula: % scavenging activity = (absorbance of control − absorbance of sample)/ (absorbance
of control)] × 100.
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CHAPTER 6
CONCLUSION

Parkinson's disease is a complex progressive neurodegenerative disorder, characterized
by gradual loss of dopaminergic neurons in the SN region of the brain. As PD is a multifactorial
disease, single target drugs would prove to be inadequate for treatment. Thus, multifunctional
drugs targeting the various pathogenic factors of PD would prove to be effective for the
treatment of PD.
Our objective was to design and develop a prodrug that will possess enhanced blood
brain barrier crossing ability compared to the neuroprotective parent compound D-264 and
characterize its physiochemical and biological properties. The introduction of modified cysteine
moiety to the 4,5,6,7-tetrahydro-benzothiazol-2-ylamine ring of D-264 molecule could further
potentiate its antioxidant property along with improving its BBB crossing ability.
After synthesizing prodrug of D-264, our next objective was to conduct ex vivo
hydrolysis studies to confirm the percentage of cleavage of prodrug to parent D-264 in the rat
brain supernatant and plasma. In this experiment, we observed

a substantial amount of

hydrolysis (57%) in the brain supernatant as compared to hydrolysis in plasma (13%) at 48h.
This experiment proved that the synthesized novel prodrug of D-264 was able to survive
premature cleavage in plasma and can efficiently be cleaved with amidases present in the brain
supernatant (Figure 20 and 21). Next, in vivo brain penetration studies confirmed the brain
penetration efficiency of the prodrug compared to D-264. In this experiment, we observed a 5.7fold increase in brain penetration of the prodrug compared to parent D-264 at 4 h using 50
µM/kg as depicted in Figure 23.
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Further, DPPH antioxidant assay confirmed significant anti-oxidant property of the
prodrug and its activity is comparable to well-known antioxidant L-cysteine.

In addition,

conjugation of modified cystiene moiety enhanced the activity of prodrug compared to D-264
(Figure 25).
Overall, in our approach towards addressing the symptomatic and neuroprotective diseasemodifying treatment of PD, we have designed a novel efficient brain penetrating prodrug of
neuroprotective anti-parkinsonian drug D-264 with additional anti-oxidant activity. However,
further in vitro and in vivo studies need to be carried out to fully establish the potential
neuroprotective effects of the newly synthesized prodrug.

Future goals
In order to establish the potential neuroprotective effects of prodrug of D-264 further in vitro and
in vivo studies needs to be carried out.
1. In vivo blood brain barrier crossing ability of prodrug of D-264 in comparison with D-264
alone by reversal of Reserpine induced hypolocomotion in rats
2. Behavioral changes and neuroprotection of prodrug of D-264 against 6-OHDA lesioned rats or
MPTP- rat model.
3. Effect of prodrug of D-264 against MPTP-induced depletion of striatal DA content.
4. Effect of prodrug of D-264 against MPTP-induced SNpc DAergic cell loss.
5. Effect of prodrug of D-264 on brain GSH levels against 6-OHDA/MPTP toxicity.
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ABSTRACT
SYNTHESIS AND CHARACTERIZATION OF BRAIN PENETRANT PRODRUG OF
NEUROPROTECTIVE D-264: POTENTIAL DISEASE MODIFYING TREATMENT
AGENT FOR PARKINSON’S DISEASE
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Parkinson's disease (PD) is a complex neurodegenerative disorder with progressive loss
of dopamanergic neurons in the substantia nigra region of the brain and accumulation of
intracytoplasmic inclusions called ‘Lewy bodies’. PD is characterized by tremors, rigidity,
slowness of movement, bradykinesia and postural imbalances. Although the etiology of PD is
not well understood, it is well established that oxidative stress, mitochondrial dysfunction,
alpha-synuclein aggregation play a central role in the pathogenesis of PD. Current treatment
methods are based on symptomatic relief without addressing the underlying pathophysiological
factors responsible for the disease. It is important to develop therapies which can address these
complex pathogenesis of the disease process and providing symptomatic relief as well. Towards
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development of novel multifunctional dopamine D2/D3 agonist drugs for the treatment of
Parkinson’s disease (PD), D-264 was previously synthesized in our lab. D-264, a potent D3
preferring agonist, is one of our lead compounds which showed high neuroprotection in MPTP &
Lactacystin PD animal models. However, this drug seems to have minimal brain penetration. In
order to further enhance the efficacy and bio-availability of D-264 in the brain, we have designed
a cysteine based D-264 prodrug as a substantial amount of research points out an important role of
antioxidants such as L-cysteine in reducing the oxidative stress associated with PD.

To this end, we have evaluated the ex vivo hydrolysis pattern of synthesized prodrug to
yield active D-264 in brain & plasma solutions using RP-HPLC.

In order to evaluate the

efficiency of prodrug in crossing blood-brain barrier, in vivo brain penetration studies were
performed and efficiency of hydrolysis was quantified using RP-HPLC. Further, DPPH based
anti-oxidant assay was performed to evaluate the anti-oxidant property of prodrug. Details of
prodrug design, synthesis and pharmacological evaluation will be presented. This work is
supported by NS047198 (AD).
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